TITLE

3SBIO FILES FOR SFDA APPROVAL OF HIGH-DOSE (36,000IU)

PUB. DATE
November 2008
SOURCE
Worldwide Biotech;Nov2008, Vol. 20 Issue 11, p4
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on the filing by biotechnology company 3SBio Inc. with the Chinese State Food and Drug Administration (SFD) for approval of a 36,000 IU dosage formulation of EPIAO for the treatment of anemia associated with chemotherapy in cancer patients. If approved, the high-dose drug which is designed for the rapid restoration of hemoglobin to normal level among cancer patients would be the only dosage of this kind available in China.
ACCESSION #
34959887

 

Related Articles

  • OTHER NEWS TO NOTE.  // BioWorld International;1/28/2009, Vol. 14 Issue 4, p2 

    This section offers news briefs on the biotechnology industry as of January 28, 2009. 3SBio Inc. of China has filed with the Chinese State Food and Drug Administration for approval of a TPIAO label extension for the treatment of idiopathic thrombocytopenic purpura. Algonomics NV of Belgium...

  • Neuralstem files IND application to initiate ALS trial.  // PharmaWatch: Biotechnology;Mar2009, Vol. 8 Issue 3, p10 

    The article reports on the decision of 3SBio, a biotechnology company, of filing an application to the Chinese State Food and Drug Administration for the approval of a TPIAO label extension for the treatment of idiopathic thrombocytopenic purpura (ITP). If the agency will favor the application,...

  • Other News To Note.  // BioWorld Today;7/13/2011, Vol. 22 Issue 134, p2 

    This section offers news briefs on biotechnology. A new dosage formulation of EPIAO for anemia associated with chemotherapy by 3SBio Inc. has been approved by the Chinese State Food and Drug Administration. The U.S. Food and Drug Administration (FDA) has granted an orphan drug designation to 4SC...

  • Small Staff At China's FDA Slows Regulatory Reviews. Wall, Tom // BioWorld Today;6/28/2011, Vol. 22 Issue 124, p1 

    The article reports on the shortage of staff at China's State Food and Drug Administration (SFDA) and the Center for Drug Evaluation (CDE), which slows regulatory reviews. It is noted that under the staff shortage, biotechnology companies have to wait for three to four years before their drugs...

  • II. PENDING MERGERS AND ACQUISITIONS.  // BioWorld Insight;4/1/2013, Vol. 21 Issue 14, p12 

    A chart is presented that lists U.S. biotechnology companies in pending mergers and acquisitions including 3SBio Inc., Aurinia Pharmaceuticals Inc., and Biolife Science Ltd.

  • OTHER NEWS TO NOTE.  // BioWorld International;6/10/2009, Vol. 14 Issue 23, p3 

    This section offers news briefs in the biotechnology industry. Cambridge, England-based Acacia Pharma announced the start of a Phase II study of its drug which prevents postoperative nausea and vomiting. Aposense Ltd. of Petach-Tikva, Israel has entered a partnership with GlaxoSmithKline PLC....

  • China Clears Its First Microarray Platform for in Vitro Diagnostics to Accelerate Personalized Medicine.  // Biomedical Market Newsletter;2/21/2012, Vol. 21, p1 

    The article provides information on the approval of GeneChip (®) System 3000Dx v.2, a microarray instrument system from Affymetrix Inc. by China State Food & Drug Administration (SFDA) for in vitro diagnostic use. It is the first microarray instrument system to be granted SFDA registration...

  • OTHER NEWS TO NOTE.  // BioWorld International;6/4/2008, Vol. 13 Issue 23, p3 

    This section offers news briefs on the biotechnology industry. 3SBio Inc. signed a development-commercialization deal with AMAG Pharmaceuticals Inc. to obtain Chinese approval and to market ferumoxytol. Celgene International Sarl withdrew its European marketing application for lenalidomide in...

  • OTHER NEWS TO NOTE.  // BioWorld Today;1/11/2010, Vol. 21 Issue 6, p3 

    This section offers news briefs concerning the biotechnology industry. 3SBio Inc. has submitted an application for a registration trial to the China's State Food and Drug Administration for AMAG Pharmaceuticals Inc.'s Feraheme intravenous iron drug. Adeona Pharmaceuticals Inc. has received a...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics